Prophylactic gastrostomy placement and early tube feeding may limit loss of weight during chemoradiotherapy for advanced head and neck cancer, a preliminary study

被引:98
作者
Wiggenraad, R. G. J.
Flierman, L.
Goossens, A.
Brand, R.
Verschuur, H. P.
Croll, G. A.
Moser, L. E. C.
Vriesendorp, R.
机构
[1] Hague Med Ctr, Dept Radiotherapy, NL-2501 CK The Hague, Netherlands
[2] Leiden Univ, Med Ctr, Dept Nutr Support, NL-2300 RA Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-2300 RA Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, NL-2300 RA Leiden, Netherlands
[5] Hague Med Ctr, Dept Internal Med, The Hague, Netherlands
[6] LUMC, MCH Multidisciplinary Head & Neck Working Grp, Leiden, Netherlands
关键词
D O I
10.1111/j.1749-4486.2007.01533.x
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objectives: Most patients with advanced head and neck cancer receiving chemoradiotherapy need tube feeding for at least some weeks. For these periods gastrostomy tubes have advantages over nasogastric tubes. Tube feeding may start earlier and thus loss of weight may be limited if the gastrostomy tube already is in place. The objective of this study is to analyse the results of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement and early tube feeding. Design: Retrospective chart review. Setting: Multidisciplinary head and neck oncology team in a general hospital. Participants: Fifty consecutive patients with unresectable stage III and IV head and neck cancer treated with concurrent chemoradiotherapy. In all patients prophylactic PEG placement was performed. Tube feeding was initiated if food-intake became insufficient or loss of weight occurred. Main outcome measures: Loss of weight during treatment, complication rate, PEG duration. Results: The mean loss of weight during treatment for all patients was only 2.8%. One complication of tube placement occurred: a colon perforation, treated successfully by surgery. The median duration of the PEG was 178 days. Three of the 17 patients (18%) with no evidence of disease (NED) still had a PEG at their last follow-up visit. Of the 26 patients who died of their cancer, 13 used the PEG until death. Conclusions: Loss of weight was limited after prophylactic gastrostomy placement and early tube feeding. Moreover, the complication rate was low. In 82% of the NED patients the PEG could eventually be removed.
引用
收藏
页码:384 / 390
页数:7
相关论文
共 25 条
[1]  
Abuksis G, 2000, AM J GASTROENTEROL, V95, P128
[2]   Metastatic head and neck carcinoma to a percutaneous endoscopic gastrostomy site [J].
Adelson, RT ;
Ducic, Y .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (04) :339-343
[3]  
Adelstein DJ, 1997, HEAD NECK-J SCI SPEC, V19, P567, DOI 10.1002/(SICI)1097-0347(199710)19:7<567::AID-HED2>3.0.CO
[4]  
2-5
[5]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[6]   Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy [J].
Adelstein, DJ ;
Saxton, JP ;
Lavertu, P ;
Rybicki, LA ;
Esclamado, RM ;
Wood, BG ;
Strome, M ;
Carroll, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1405-1410
[7]   Does feeding tube placement predict for long-term swallowing disability after radiotherapy for head and neck cancer? [J].
Al-Othman, MOF ;
Amdur, RJ ;
Morris, CG ;
Hinerman, RW ;
Mendenhall, WM .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2003, 25 (09) :741-747
[8]   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804
[9]   Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 gortec phase II trial [J].
Calais, G ;
Bardet, E ;
Sire, C ;
Alfonsi, M ;
Bourhis, J ;
Rhein, B ;
Tortochaux, J ;
Man, YTK ;
Auvray, H ;
Garaud, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (01) :161-166
[10]   Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma [J].
Calais, G ;
Alfonsi, M ;
Bardet, E ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Oudinot, P ;
Bertrand, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (24) :2081-2086